Director – Market Access Marketing - Sleep
About the job
- Minimum of 10+ years of progressive commercial pharmaceutical or biopharmaceutical experience, with substantial focus in Market Access Marketing, Payer Strategy, or related commercial functions.
- Proven ability to independently develop and drive significant components of a commercial access strategy and navigate complex, evolving reimbursement environments.
- Demonstrated track record of aligning cross-functional teams and driving consensus as a senior individual contributor.
- Deep knowledge of United States healthcare delivery models, pharmacy benefit manager and health plan dynamics, formulary tier design, utilization management criteria, and specialty distribution channels.
- Extensive experience presenting strategic plans and business cases to senior management and serving as a credible thought partner to executive leadership.
- A bachelor's degree is required.
- In partnership with the Executive Director, lead development of annual and long-range Market Access strategic plans for the Sleep Franchise, drive their execution, and establish clear objectives and key performance indicators aligned with brand imperatives.
- Drive development of the overarching Payer Value Proposition, collaborating with Health Economics and Outcomes Research, Medical Affairs, and Commercial Brand Marketing to translate clinical differentiation and economic evidence into payer access strategies for the franchise-level narrative.
- Serve as a subject matter expert and strategic liaison to cross-functional partners; independently drive commercial alignment on net revenue and coverage goals, and represent Market Access insights to inform evidence generation and pipeline strategy.
- Formulate key business questions and drive strategic intelligence through advanced market research and policy tracking; identify and assess environmental shifts and provide strategic recommendations to the Executive Director.
- Design and govern the strategic framework for Market Access pull-through, define operational priorities, and lead development of tools and resources for Payer Account Executives, Access and Reimbursement Managers, and Field Sales.
- An MBA or another advanced degree (MS, MPH, or PharmD) is strongly preferred.
- Experience in Neuroscience or Sleep therapeutic areas and lifecycle management.
About the company
Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Dublin, Ireland
Founded
2003
Get referred to Jazz Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue hit $1.21 billion; Jazz raised full-year guidance to $4.68 billion.
- Actio's ABS-1230 adds first-in-class KCNT1 epilepsy upside after the September 15, 2026 close.
- Oncology revenue exceeded $1 billion in 2025, driven by Zepzelca and Ziihera.
What critics are saying
- Xywav faces Lupin, Teva, and Tris patent fights; generic entry threatens 2027 cash flow.
- Xywav and EPIDIOLEX still dominate value; one patent loss or safety issue would crush earnings.
- Jazz paid $820 million for Actio before registrational proof; ABS-1230 can still fail.
What makes Jazz Pharmaceuticals unique
- Ziihera launched August 2026, targeting $3B-$5B across HER2-positive tumors.
- EPIDIOLEX holds exclusivity into the late 2030s and now funds four new trials.
- Xywav's low-sodium oxybate formulation keeps narcolepsy patients despite generic Xyrem pressure.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Health Insurance
- Dental Insurance
- Vision Insurance
- 401(k) Retirement Plan
- Paid Vacation
Growth & Insights and Company News
6 month growth
0%1 year growth
1%2 year growth
0%Jazz Pharmaceuticals has won US Food and Drug Administration (FDA) approval for its cancer drug Ziihera. The approval raised the drug's projected peak sales range. Separately, chief commercial officer Samantha Pearce plans to retire by June 30, 2027, or when a successor is appointed. Jazz has started an internal and external search. In its second-quarter 2026 update, Jazz reported revenue of $1,208.3 million and raised full-year 2026 guidance to $4.60–4.75 billion. The share price still fell 7.6% after earnings. Simply Wall St's narrative projects revenue of $5.7 billion and earnings of $1.7 billion by 2029, implying a fair value of $294.27 a share.
Jazz Pharmaceuticals reported its oncology revenue surpassed $1 billion in 2025, marking a 32% year-over-year increase. The growth follows three recent product launches, including zanidatamab, Modeyso and Zepzelca's FORTE regimen. The company raised zanidatamab's estimated peak-sales opportunity to $3 billion-$5 billion. Jazz aims to increase HER2-directed treatment adoption in gastroesophageal cancer, where only 60% of eligible HER2-positive patients currently receive such therapy. Jazz estimates the US incidence of HER2-positive gastroesophageal adenocarcinoma at approximately 8,000 patients, with a labelled population of 3,000 to 4,000 patients. The company is also developing zanidatamab for biliary tract cancer, colorectal cancer, non-small cell lung cancer and breast cancer. Jazz maintains commercial investment whilst preserving financial flexibility for acquisitions across oncology, epilepsy and sleep disorders.
Jazz Pharmaceuticals' stock has risen 29.7% over the past six months, outpacing the S&P 500 by 17 percentage points to reach $240.49 per share. However, analysts point to concerning trends in the company's fundamentals. The company's adjusted operating margin has declined by 2.6 percentage points over five years, despite revenue growth that should have improved economies of scale. Its trailing 12-month adjusted operating margin stood at 41.7%. Additionally, Jazz Pharmaceuticals' five-year average return on invested capital was just 2.7%, below the typical cost of capital for healthcare companies. This suggests mediocre efficiency in deploying capital for growth. The stock currently trades at 9.6× forward price-to-earnings ratio. Analysts consider this valuation reasonable but believe the company's weakening fundamentals present downside risk.
Jazz Pharmaceuticals has priced an upsized $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion. The offering, conducted through its wholly-owned subsidiary Jazz Investments I Limited, is expected to close on 31 August 2026. The notes will mature on 15 September 2032 and are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 principal amount, equivalent to an exchange price of approximately $355.24 per share. This represents a 42.5% premium above the last reported sale price on 26 August 2026. The company will use net proceeds of approximately $1,079 million for general corporate purposes. Concurrently, Jazz Pharmaceuticals agreed to repurchase approximately $225 million of its ordinary shares from note purchasers at $249.29 per share, using existing cash on hand.
Jazz Pharmaceuticals has launched Ziihera in the US following FDA approval for first-line treatment of HER2-positive, unresectable or metastatic gastroesophageal adenocarcinoma. The drug can be used with tislelizumab and chemotherapy, or with chemotherapy alone for certain patients. In the Phase III HERIZON-GEA-01 trial, Ziihera-based regimens reduced the risk of disease progression or death by 35%. The triplet regimen extended median overall survival to 26.4 months, a 28% reduction in death risk versus trastuzumab. Jazz estimates the US addressable market at 3,000–4,000 patients annually and raised Ziihera's peak sales outlook to $3 billion–$5 billion. The company plans to leverage existing commercial infrastructure whilst pursuing additional cancer indications and international regulatory filings.